Philips reports strong Q1 with 6% order growth, 4% sales rise, and margin expansion; 2026 outlook confirmed.

Philips delivered a strong start to 2026 with a 6% increase in comparable order intake and a 4% rise in comparable sales, driven by growth across all segments, especially Personal Health. The company expanded its adjusted EBITA margin by 40 basis points to 9.0%, despite challenges from tariffs and cost inflation, supported by innovation and productivity gains. Philips also secured regulatory approvals for AI-powered health technologies and strengthened strategic partnerships. The company reiterated its full-year 2026 outlook, expecting 3%-4.5% sales growth, a 12.5%-13.0% adjusted EBITA margin, and free cash flow between EUR 1.3-1.5 billion.